Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for AC Immune (ACIU : NSDQ)
 
 • Company Description   
AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland.

Number of Employees: 143

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.15 Daily Weekly Monthly
20 Day Moving Average: 105,142 shares
Shares Outstanding: 83.48 (millions)
Market Capitalization: $262.96 (millions)
Beta: 0.86
52 Week High: $8.64
52 Week Low: $2.46
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -17.32% -6.89%
12 Week -16.00% -7.66%
Year To Date -36.36% -22.99%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
EPFL INNOVATION PARK BUILDING B
-
1015 LAUSANNE,V8 1015
CHE
ph: 41-21-345-9121
fax: 41-21-345-9120
ir@acimmune.com http://www.acimmune.com
 
 • General Corporate Information   
Officers
Andrea Pfeifer - Chief Executive Officer and Director
Douglas Williams - Chairman and Director
Joerg Hornstein - Chief Financial Officer
Thomas Graney - Director
Werner Lanthaler - Director

Peer Information
AC Immune (CORR.)
AC Immune (RSPI)
AC Immune (CGXP)
AC Immune (BGEN)
AC Immune (GTBP)
AC Immune (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: H00263105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 83.48
Most Recent Split Date: (:1)
Beta: 0.86
Market Capitalization: $262.96 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.99 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.13
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 10.71%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -35.82
12/31/21 - -36.04
09/30/21 - -36.35
ROA
03/31/22 - -32.01
12/31/21 - -32.22
09/30/21 - -32.65
Current Ratio
03/31/22 - 14.87
12/31/21 - 10.12
09/30/21 - 13.74
Quick Ratio
03/31/22 - 14.87
12/31/21 - 10.12
09/30/21 - 13.74
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -7,453.11
Book Value
03/31/22 - 2.78
12/31/21 - 3.49
09/30/21 - 2.69
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©